

# BPAL-L Implementation Progress report



## BPAL-L ROLL-OUT

### *UPDATES, CRITICAL ENABLERS & CHALLENGES*

---

**Ms Y Kock**

---

**23<sup>rd</sup> May 2024**

# Introduction

- Revolutionary changes has been made in the DR-TB platform

- BPaL-L/M was implemented on the  
1<sup>st</sup> of September 2023
- This is a key intervention of the TB Recovery Plan:
  - *Improve retention in care*



Diagnostics	Regimens	Novel drugs
Xpert MTB/RIF	9-month injectable	Linezolid
Xpert MTB/RIF Ultra	9-month all oral	Delamanid
Xpert MTB/XDR	6-month BPaL-M	Pretomanid

# DR-TB Regimens Over Time – Key Facts



Period	RR/MDR-TB Shorter Regimen	RR/MDR-TB Longer Regimen	XDR-TB Longer Regimen
2011 – 2016	<ul style="list-style-type: none"> <li>• Not applicable</li> </ul>	<ul style="list-style-type: none"> <li>• 24 months (at least)</li> <li>• 5 drugs</li> <li>• <b>180 injections + 7 200 pills</b></li> </ul>	<ul style="list-style-type: none"> <li>• 24 months (at least)</li> <li>• 7 drugs</li> <li>• <b>180 injections + 7 200 pills</b></li> </ul>
2017 – 2018 (Aug)	<ul style="list-style-type: none"> <li>• 9 – 11 months</li> <li>• 7 drugs</li> <li>• <b>Up to 180 injections + at least 2 880 pills</b></li> </ul>	<ul style="list-style-type: none"> <li>• 18 – 20 months</li> <li>• 5 drugs</li> <li>• <b>Up to 180 injections + at least 5 400 pills</b></li> </ul>	<ul style="list-style-type: none"> <li>• 18 – 20 months</li> <li>• 5 drugs</li> <li>• All-oral: <b>at least 3 968 pills</b></li> </ul>
2018 (Aug) – 2023	<ul style="list-style-type: none"> <li>• 9 – 11 months</li> <li>• 7 drugs</li> <li>• All-oral: <b>at least 3 038 pills</b></li> </ul>	<ul style="list-style-type: none"> <li>• 18 – 20 months</li> <li>• 5 drugs</li> <li>• All-oral: <b>at least 5 048 pills</b></li> </ul>	<ul style="list-style-type: none"> <li>• 18 – 20 months</li> <li>• 5 drugs</li> <li>• All-oral: <b>at least 3 968 pills</b></li> </ul>

# New Regimen – BPaL-L





# DRUG RESISTANT TB CAN BE CURED



## NEW REGIMEN for MDR-TB BPaL – L is better for you!



ONLY 6 months of treatment

3 to 4 medicines

90% cure rate

Simplified regimen



The new regimen for MDR-TB patients has many advantages, including:

- Fewer pills required – only 23 pills per week
- Shorter treatment – only 6 months
- Fewer facility visits, which means a lower costs for you to get treated

Speak to your healthcare worker today to find out if you are eligible!



# UPDATES

## CLINICAL MANAGEMENT OF RIFAMPICIN-RESISTANT TUBERCULOSIS

Updated Clinical Reference Guide

September 2023

- Donation acquired and stock distributed
- Guidelines updated and training materials/ manual developed
- Phase-in approach
  - Training conducted across the 9 provinces
  - District training
- Dashboard developed

### RSA Department of Health

#### BPaL Programme Dashboard

##### Aim

Monitor the implementation of the new 6-month TB treatment regimen  
Monitor accurate, clean, timeous data capturing

##### Inclusion criteria

All patients initiated on RR-TB treatment  
Patients above 15 years of age  
All patients registered with Pretomanid in their current treatment

##### Exclusion criteria:

Patients diagnosed with XDR-TB treatment  
Patients less than 15 years of age  
Pregnant women

# BPaL-L/M enrolment to date:

- 49 of the 52 districts are reporting BPaL-L/M initiation, even though 83% of patients are enrolled
- Total number of patients enrolled since 1<sup>st</sup> September 2023

Patients on BPaL-L/M by Province									
Province	Sep-2023	Oct-2023	Nov-2023	Dec-2023	Jan-2024	Feb-2024	Mar-2024	Apr-2024	Total
EC	71	72	75	53	80	121	84	89	645
FS			6	7	8	13	18	8	60
GP	17	49	61	37	44	46	46	52	352
KZN	8	37	71	92	114	106	68	54	550
LP	1	15	18	12	10	19	13	15	103
MP		6	18	17	19	26	17	20	123
NC	11	18	23	15	19	20	19	25	150
NW	8	14	12	8	10	12	9	8	81
WC		1	7	25	70	77	71	46	297
<b>Total</b>	<b>116</b>	<b>212</b>	<b>291</b>	<b>266</b>	<b>374</b>	<b>440</b>	<b>345</b>	<b>317</b>	<b>2 361</b>



# BPaL-L/M, as % of BPaL eligible patients

Patients on BPaL-L/M as % of BPaL-L/M eligible by Province								
Province	Sep-2023	Oct-2023	Nov-2023	Dec-2023	Jan-2024	Feb-2024	Mar-2024	Apr-2024
EC	46%	51%	54%	51%	65%	70%	73%	85%
FS			20%	50%	40%	68%	90%	100%
GP	26%	54%	74%	74%	77%	78%	85%	93%
KZN	7%	27%	53%	71%	73%	79%	67%	70%
LP	5%	56%	82%	92%	83%	83%	93%	88%
MP		19%	62%	74%	70%	72%	81%	87%
NC	44%	95%	100%	94%	95%	100%	83%	93%
NW	33%	48%	48%	67%	67%	57%	90%	80%
WC		1%	6%	32%	56%	72%	75%	75%
<b>Total</b>	<b>21%</b>	<b>33%</b>	<b>48%</b>	<b>61%</b>	<b>67%</b>	<b>74%</b>	<b>76%</b>	<b>83%</b>



# Key facts



Medicine	What do patients need	Unit(s)	Regimen length
Bedaquiline; 100mg; Tablet; 188 Tablets	1	pack	6-month course
Delamanid; 50mg; Tablet; 48 Tablets	15	packs	12-month course
Pretomanid; 200mg; Tablet; 30 Tablets	6	packs	6-month course
Levofloxacin; 500mg; Tablet; 28 Tablets	12*	packs	6-month course at 1000mg per day
	6*	packs	6-month course in a 750mg combination
Levofloxacin; 250mg; Tablet; 28 Tablets	6*	packs	6-month course in a 750mg combination
Linezolid; 600mg; Tablet; 10 Tablets	18	packs	6-month course

\* These figures are dispensed in 28 tablet packs, indicating 1 month = 4 weeks; increase to 7 or 13 packs to accommodate extra





**health**

Department:  
Health  
REPUBLIC OF SOUTH AFRICA



# Critical enablers

- Buy-in was of utmost importance (on all levels)
- Multi-disciplinary approach
  - Clinicians, pharmacist, partners
- Communication and feedback mechanism is key
  - Support groups, WhatsApps and dashboard
- Live data capturing enables proactive management of rollout



# CHALLENGES

- Inadequate supply of pretomanid in some provinces
- Unavailability of ancillary drugs to combat AE's on all level
- Inadequate monitoring and evaluation
  - Data incompleteness
- Patient education and support



Thank you

